JP7821119B2 - Ｈｌａクラスｉ ｍｈｃの細胞切除 - Google Patents

Ｈｌａクラスｉ ｍｈｃの細胞切除

Info

Publication number
JP7821119B2
JP7821119B2 JP2022564243A JP2022564243A JP7821119B2 JP 7821119 B2 JP7821119 B2 JP 7821119B2 JP 2022564243 A JP2022564243 A JP 2022564243A JP 2022564243 A JP2022564243 A JP 2022564243A JP 7821119 B2 JP7821119 B2 JP 7821119B2
Authority
JP
Japan
Prior art keywords
cells
expression
cell
vector
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022564243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522985A5 (https=
JP2023522985A (ja
Inventor
フィリップ ジー． アシュトン－リッカルト，
Original Assignee
エーゼットセラピーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーゼットセラピーズ， インコーポレイテッド filed Critical エーゼットセラピーズ， インコーポレイテッド
Publication of JP2023522985A publication Critical patent/JP2023522985A/ja
Publication of JP2023522985A5 publication Critical patent/JP2023522985A5/ja
Application granted granted Critical
Publication of JP7821119B2 publication Critical patent/JP7821119B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
JP2022564243A 2020-04-23 2021-04-23 Ｈｌａクラスｉ ｍｈｃの細胞切除 Active JP7821119B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014344P 2020-04-23 2020-04-23
US63/014,344 2020-04-23
PCT/US2021/028808 WO2021216978A1 (en) 2020-04-23 2021-04-23 Cellular ablation of hla-class i mhc

Publications (3)

Publication Number Publication Date
JP2023522985A JP2023522985A (ja) 2023-06-01
JP2023522985A5 JP2023522985A5 (https=) 2024-05-01
JP7821119B2 true JP7821119B2 (ja) 2026-02-26

Family

ID=75888299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564243A Active JP7821119B2 (ja) 2020-04-23 2021-04-23 Ｈｌａクラスｉ ｍｈｃの細胞切除

Country Status (6)

Country Link
US (1) US20230212585A1 (https=)
EP (1) EP4139458A1 (https=)
JP (1) JP7821119B2 (https=)
CN (1) CN116134144A (https=)
IL (1) IL297489A (https=)
WO (1) WO2021216978A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287129A1 (en) 2004-05-18 2005-12-29 Cicciarelli James C Vectors and methods for long-term immune evasion to prolong transplant viability
WO2018208837A1 (en) 2017-05-08 2018-11-15 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO2005108572A1 (de) * 2004-05-06 2005-11-17 Medizinische Hochschule Hannover Verbindungen und verfahren zur immunsuppression
JP6681837B2 (ja) * 2014-03-11 2020-04-15 セレクティスＣｅｌｌｅｃｔｉｓ 同種移植に適合するｔ細胞を作製するための方法
US9997807B2 (en) 2014-12-24 2018-06-12 East Penn Manufacturing Co. Vibration resistant valve assembly for lead acid batteries
JP2019532640A (ja) * 2016-09-29 2019-11-14 ナントクエスト インコーポレイテッド 免疫原性が低下したｈｌａクラスｉ欠損ｎｋ−９２細胞
EP3441461A1 (en) * 2017-08-11 2019-02-13 Baylor College of Medicine Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
EP3773629A4 (en) 2018-03-27 2022-01-19 AZTherapies, Inc. CAR-TREG-BASED THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
KR102691932B1 (ko) * 2019-04-03 2024-08-06 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287129A1 (en) 2004-05-18 2005-12-29 Cicciarelli James C Vectors and methods for long-term immune evasion to prolong transplant viability
WO2018208837A1 (en) 2017-05-08 2018-11-15 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof

Also Published As

Publication number Publication date
US20230212585A1 (en) 2023-07-06
CN116134144A (zh) 2023-05-16
IL297489A (en) 2022-12-01
WO2021216978A1 (en) 2021-10-28
EP4139458A1 (en) 2023-03-01
JP2023522985A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
Ackerman et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
US11872286B2 (en) Compositions and methods for delivery of nucleic acids to cells
EP4678184A2 (en) Engineered chimeric fusion protein compositions and methods of use thereof
CN109803983B (zh) 靶向nkg2dl的特异性嵌合抗原受体t细胞，其制备方法和应用
IL274299B1 (en) Methods, compositions and components for editing TGFBR2 by CRISPR-Cas9 in T cells for immunotherapy
US20210381006A1 (en) Method for activation/proliferation of t cells
US20220001031A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
WO2020033791A1 (en) Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
US20220133917A1 (en) Small Molecules for Dual Function Positron Emission Tomography (PET) and Cell Suicide Switches
JP2020536514A (ja) ＨＰＫ１を標的とするｇＲＮＡ及びＨＰＫ１遺伝子の編集方法
US20220378824A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
JP2023544970A (ja) 細胞への核酸の送達のための組成物及び方法
WO2018052142A1 (ja) 遺伝子改変細胞及びその作製方法
US20260117212A1 (en) Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
EP3766977A1 (en) Genetically modified cell and producing method therefor
JP7821119B2 (ja) Ｈｌａクラスｉ ｍｈｃの細胞切除
US20260042815A1 (en) Universal t cells and compositions and methods of use thereof
HK40126591A (zh) 通用t细胞和组合物及它们的使用方法
WO2025259362A1 (en) Enhancements for proximal signaling car activation
WO2025194114A1 (en) Compositions and methods for modulation of mcj in cellular therapies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260213

R150 Certificate of patent or registration of utility model

Ref document number: 7821119

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150